Brent R. Logan, PhD

Director & Professor

Locations

Biostatistics

Contact Information

Education

PhD, Northwestern University, Evanston, IL, 2001
MS, Northwestern University, Evanston, IL, 1998
BS, Vanderbilt University, Nashville, TN, 1996

Research Experience

Multiple Comparison Procedures

Research Interests

Dr. Brent Logan joined the Division of Biostatistics in the Summer of 2001. He has methodological research interests in multiple comparison procedures, clinical trial design, and survival analysis. Research in multiple testing includes methods for analyzing multiple endpoints in clinical trials, analysis of dose-response studies, and multiplicity adjustment in functional MRI studies. His interests in clinical trial design include randomized phase 2 clinical trials and biologic assignment trials in bone marrow transplant studies. Recent work in survival analysis has focused on inference for competing risks and multistate models using pseudo-value regression, analysis in the presence of crossing survival curves, and methods for the analysis of complex bone marrow transplant data. He is a biostatistician for the Blood and Marrow Transplant Clinical Trials Network (BMTCTN) and the Center for International Blood and Marrow Transplant Research (CIBMTR), as well as a statistical consultant for the National Marrow Donor Program.

Curriculum Vitae

Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.

(Guru Murthy GS, Logan BR, Bo-Subait S, Beitinjaneh A, Devine S, Farhadfar N, Gowda L, Hashmi S, Lazarus H, Nathan S, Sharma A, Yared JA, Stefanski HE, Pulsipher MA, Hsu JW, Switzer GE, Panch SR, Shaw BE.) Am J Hematol. 2023 Apr;98(4):608-619 PMID: 36606713 SCOPUS ID: 2-s2.0-85146394154 01/07/2023
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.

(Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J.) Transplant Cell Ther. 2023 Mar;29(3):208.e1-208.e6 PMID: 36584941 PMCID: PMC9992261 SCOPUS ID: 2-s2.0-85146784394 12/31/2022
Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation.

(Friend BD, Broglie L, Logan BR, Chhabra S, Bupp C, Schiller G, Beitinjaneh A, Perez MAD, Guilcher GMT, Hashem H, Hildebrandt GC, Krem MM, Lazarus HM, Nishihori T, Nusrat R, Rotz SJ, Wirk B, Wieduwilt M, Pasquini M, Savani BN, Stadtmauer EA, Sorror ML, Thakar MS.) Transplant Cell Ther. 2023 Feb;29(2):123.e1-123.e10 PMID: 36442769 PMCID: PMC9911376 SCOPUS ID: 2-s2.0-85144499032 11/29/2022
Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases.

(Broglie L, Friend BD, Chhabra S, Logan BR, Bupp C, Schiller G, Savani BN, Stadtmauer E, Abraham AA, Aljurf M, Badawy SM, Perez MAD, Guinan EC, Hashem H, Krem MM, Lazarus HM, Rotz SJ, Wirk B, Yared JA, Pasquini M, Thakar MS, Sorror ML.) Transplant Cell Ther. 2023 Feb;29(2):125.e1-125.e9 PMID: 36442768 PMCID: PMC9911359 SCOPUS ID: 2-s2.0-85144512149 11/29/2022
Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102.

(Cusatis R, Martens MJ, Nakamura R, Cutler CS, Saber W, Lee SJ, Logan BR, Shaw BE, Gregory A, D'Souza A, Hamilton BK, Horowitz MM, Flynn KE.) Am J Hematol. 2023 Feb;98(2):229-250 PMID: 36251401 PMCID: PMC9839494 SCOPUS ID: 2-s2.0-85142150726 10/18/2022
Aberrant T-cell exhaustion in severe combined immunodeficiency survivors with poor T-cell reconstitution after transplantation.

(Labrosse R, Boufaied I, Bourdin B, Gona S, Randolph HE, Logan BR, Bourbonnais S, Berthe C, Chan W, Buckley RH, Parrott RE, Cuvelier GDE, Kapoor N, Chandra S, Dávila Saldaña BJ, Eissa H, Goldman FD, Heimall J, O'Reilly R, Chaudhury S, Kolb EA, Shenoy S, Griffith LM, Pulsipher M, Kohn DB, Notarangelo LD, Pai SY, Cowan MJ, Dvorak CC, Haddad É, Puck JM, Barreiro LB, Decaluwe H.) J Allergy Clin Immunol. 2023 Jan;151(1):260-271 PMID: 35987350 PMCID: PMC9924130 SCOPUS ID: 2-s2.0-85138535551 08/21/2022
Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians.

(Broglie L, Friend BD, Chhabra S, Bupp C, Schiller GJ, Logan B, Pasquini MC, Savani B, Stadtmauer EA, Thakar MS, Sorror M.) Leuk Lymphoma. 2022 Oct;63(10):2507-2510 PMID: 35583292 PMCID: PMC9875328 SCOPUS ID: 2-s2.0-85130807981 05/19/2022
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.

(DeZern AE, Eapen M, Wu J, Talano JA, Solh M, Dávila Saldaña BJ, Karanes C, Horwitz ME, Mallhi K, Arai S, Farhadfar N, Hexner E, Westervelt P, Antin JH, Deeg HJ, Leifer E, Brodsky RA, Logan BR, Horowitz MM, Jones RJ, Pulsipher MA.) Lancet Haematol. 2022 Sep;9(9):e660-e669 PMID: 35907408 PMCID: PMC9444987 SCOPUS ID: 2-s2.0-85135889621 07/31/2022
The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials.

(Farhadfar N, Ahn KW, Bo-Subait S, Logan B, Stefanski HE, Hsu JW, Panch S, Confer D, Liu H, Badawy SM, Beitinjaneh A, Diaz MA, Hildebrandt GC, Kelkar AH, Lazarus HM, Murthy HS, Preussler JM, Schears RM, Sharma A, van der Poel M, Bruce JG, Pulsipher MA, Shaw BE, Wingard JR, Switzer GE.) Transplant Cell Ther. 2022 Sep;28(9):603.e1-603.e7 PMID: 35688325 PMCID: PMC9427696 SCOPUS ID: 2-s2.0-85134804662 06/11/2022
Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC.

(Cuvelier GDE, Logan BR, Prockop SE, Buckley RH, Kuo CY, Griffith LM, Liu X, Yip A, Hershfield MS, Ayoub PG, Moore TB, Dorsey MJ, O'Reilly RJ, Kapoor N, Pai SY, Kapadia M, Ebens CL, Forbes Satter LR, Burroughs LM, Petrovic A, Chellapandian D, Heimall J, Shyr DC, Rayes A, Bednarski JJ, Chandra S, Chandrakasan S, Gillio AP, Madden L, Quigg TC, Caywood EH, Dávila Saldaña BJ, DeSantes K, Eissa H, Goldman FD, Rozmus J, Shah AJ, Vander Lugt MT, Thakar MS, Parrott RE, Martinez C, Leiding JW, Torgerson TR, Pulsipher MA, Notarangelo LD, Cowan MJ, Dvorak CC, Haddad E, Puck JM, Kohn DB.) Blood. 2022 Aug 18;140(7):685-705 PMID: 35671392 PMCID: PMC9389638 SCOPUS ID: 2-s2.0-85135995959 06/08/2022
Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012.

(Brunstein CG, O'Donnell PV, Logan B, Dawson P, Costa L, Cutler C, Craig M, Hogan W, Horowitz MM, Horwitz ME, Karanes C, Magenau JM, Malone A, McCarty J, McGuirk JP, Morris LE, Rezvani AR, Salit R, Vasu S, Eapen M, Fuchs EJ, Blood and Marrow Transplant Clinical Trials Network.) Transplant Cell Ther. 2022 Jul;28(7):406.e1-406.e6 PMID: 35390529 PMCID: PMC9253061 SCOPUS ID: 2-s2.0-85130454080 04/08/2022
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.

(Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA.) J Clin Oncol. 2022 Feb 01;40(4):356-368 PMID: 34855460 PMCID: PMC8797487 SCOPUS ID: 2-s2.0-85123901255 12/03/2021